Biomm S.A (BIOM3) - Net Assets

Latest as of September 2025: R$284.10 Million BRL ≈ $55.75 Million USD

Based on the latest financial reports, Biomm S.A (BIOM3) has net assets worth R$284.10 Million BRL (≈ $55.75 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$485.03 Million ≈ $95.17 Million USD) and total liabilities (R$200.93 Million ≈ $39.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Biomm S.A to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets R$284.10 Million
% of Total Assets 58.57%
Annual Growth Rate 19.8%
5-Year Change 37.24%
10-Year Change 128.25%
Growth Volatility 65.78

Biomm S.A - Net Assets Trend (2004–2024)

This chart illustrates how Biomm S.A's net assets have evolved over time, based on quarterly financial data. Also explore BIOM3 total assets for the complete picture of this company's asset base.

Annual Net Assets for Biomm S.A (2004–2024)

The table below shows the annual net assets of Biomm S.A from 2004 to 2024. For live valuation and market cap data, see Biomm S.A market capitalisation.

Year Net Assets Change
2024-12-31 R$262.78 Million
≈ $51.56 Million
+113.75%
2023-12-31 R$122.94 Million
≈ $24.12 Million
-22.73%
2022-12-31 R$159.11 Million
≈ $31.22 Million
+42.59%
2021-12-31 R$111.59 Million
≈ $21.90 Million
-41.72%
2020-12-31 R$191.48 Million
≈ $37.57 Million
+24.70%
2019-12-31 R$153.56 Million
≈ $30.13 Million
+44.74%
2018-12-31 R$106.09 Million
≈ $20.82 Million
+78.90%
2017-12-31 R$59.30 Million
≈ $11.64 Million
-10.05%
2016-12-31 R$65.93 Million
≈ $12.94 Million
-42.73%
2015-12-31 R$115.13 Million
≈ $22.59 Million
+7.49%
2014-12-31 R$107.10 Million
≈ $21.02 Million
-1.68%
2013-12-31 R$108.94 Million
≈ $21.38 Million
+595.28%
2012-12-31 R$-22.00 Million
≈ $-4.32 Million
-151.14%
2011-12-31 R$-8.76 Million
≈ $-1.72 Million
-115.66%
2010-12-31 R$-4.06 Million
≈ $-796.84K
-26973.33%
2009-12-31 R$-15.00K
≈ $-2.94K
+99.88%
2008-12-31 R$-12.22 Million
≈ $-2.40 Million
-448.05%
2007-12-31 R$-2.23 Million
≈ $-437.37K
-172.16%
2006-12-31 R$3.09 Million
≈ $606.12K
+0.19%
2005-12-31 R$3.08 Million
≈ $604.94K
-56.50%
2004-12-31 R$7.09 Million
≈ $1.39 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Biomm S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 65364200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock R$900.00 Million 342.49%
Other Comprehensive Income R$677.00K 0.26%
Other Components R$15.75 Million 5.99%
Total Equity R$262.78 Million 100.00%

Biomm S.A Competitors by Market Cap

The table below lists competitors of Biomm S.A ranked by their market capitalization.

Company Market Cap
Kore Potash Plc
AU:KP2
$201.43 Million
OmniAb Inc.
NASDAQ:OABI
$201.54 Million
Microvision Inc
NASDAQ:MVIS
$201.56 Million
Southern Cross Media Group Ltd
AU:SXL
$201.57 Million
Arqit Quantum Inc.
NASDAQ:ARQQ
$201.28 Million
C&C International Corp.
KQ:352480
$201.21 Million
SOL-GEL TECHN. IS-10
F:4SG
$201.21 Million
Ndr Auto Components Limited
NSE:NDRAUTO
$201.15 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Biomm S.A's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 122,940,000 to 262,784,000, a change of 139,844,000 (113.7%).
  • Net loss of 77,238,000 reduced equity.
  • Share repurchases of 217,012,000 reduced equity.
  • New share issuances of 217,012,000 increased equity.
  • Other comprehensive income increased equity by 70,000.
  • Other factors increased equity by 217,012,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income R$-77.24 Million -29.39%
Share Repurchases R$217.01 Million -82.58%
Share Issuances R$217.01 Million +82.58%
Other Comprehensive Income R$70.00K +0.03%
Other Changes R$217.01 Million +82.58%
Total Change R$- 113.75%

Book Value vs Market Value Analysis

This analysis compares Biomm S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.49x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 23.18x to 3.49x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-12-31 R$0.32 R$7.50 x
2006-12-31 R$0.32 R$7.50 x
2007-12-31 R$-0.23 R$7.50 x
2008-12-31 R$-1.35 R$7.50 x
2009-12-31 R$0.00 R$7.50 x
2010-12-31 R$-0.23 R$7.50 x
2011-12-31 R$-0.49 R$7.50 x
2012-12-31 R$-1.21 R$7.50 x
2013-12-31 R$5.81 R$7.50 x
2014-12-31 R$3.32 R$7.50 x
2015-12-31 R$3.56 R$7.50 x
2016-12-31 R$2.05 R$7.50 x
2017-12-31 R$1.71 R$7.50 x
2018-12-31 R$2.41 R$7.50 x
2019-12-31 R$3.05 R$7.50 x
2020-12-31 R$3.03 R$7.50 x
2021-12-31 R$1.59 R$7.50 x
2022-12-31 R$2.16 R$7.50 x
2023-12-31 R$1.48 R$7.50 x
2024-12-31 R$2.15 R$7.50 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Biomm S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -29.39%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -54.05%
  • • Asset Turnover: 0.31x
  • • Equity Multiplier: 1.77x
  • Recent ROE (-29.39%) is above the historical average (-30.80%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 -129.91% -142.58% 0.18x 5.10x R$-4.31 Million
2006 0.19% 0.09% 0.60x 3.61x R$-302.90K
2007 0.00% -266.57% 0.21x 0.00x R$-5.10 Million
2008 0.00% -245.74% 0.25x 0.00x R$-6.19 Million
2009 0.00% -941.94% 0.06x 0.00x R$-5.73 Million
2010 0.00% -487.23% 0.18x 0.00x R$-3.87 Million
2011 0.00% -2023.81% 0.02x 0.00x R$-3.80 Million
2012 0.00% 0.00% 0.00x 0.00x R$-11.94 Million
2013 -9.23% 0.00% 0.00x 1.27x R$-20.95 Million
2014 -11.87% 0.00% 0.00x 1.68x R$-23.42 Million
2015 7.19% 0.00% 0.00x 1.99x R$-3.23 Million
2016 -69.18% 0.00% 0.00x 3.60x R$-52.20 Million
2017 -64.30% -37017.48% 0.00x 4.42x R$-44.06 Million
2018 -40.12% -2717.88% 0.01x 2.88x R$-53.17 Million
2019 -36.35% -624.02% 0.02x 2.53x R$-71.17 Million
2020 -36.96% -120.62% 0.13x 2.27x R$-89.91 Million
2021 -71.93% -74.95% 0.29x 3.31x R$-91.42 Million
2022 -58.17% -88.19% 0.26x 2.55x R$-108.47 Million
2023 -66.00% -68.65% 0.34x 2.80x R$-93.44 Million
2024 -29.39% -54.05% 0.31x 1.77x R$-103.52 Million

Industry Comparison

This section compares Biomm S.A's net assets metrics with peer companies in the Biotechnology industry.

No peer company data available for comparison.

About Biomm S.A

SA:BIOM3 Brazil Biotechnology
Market Cap
$201.38 Million
R$1.03 Billion BRL
Market Cap Rank
#16508 Global
#162 in Brazil
Share Price
R$7.50
Change (1 day)
+2.04%
52-Week Range
R$5.90 - R$10.64
All Time High
R$23.65
About

Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more